(Rac) -Cemsidomide

• Description:

  (Rac) -Cemsidomide ((Rac) -CFT7455) is the racemate of Cemsidomide (HY-144841) with antitumor activity[1]. Cemsidomide is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells.

• Product Name Alternative:

  (Rac) -CFT7455

• UNSPSC:

  12352005

• Target:

  Molecular Glues

• Type:

  Reference compound

• Related Pathways:

  PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/rac-cemsidomide.html

• Concentration:

  10mM

• Purity:

  98.52

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C1N(C2C(NC(CC2)=O)=O)C3=CC=C(C4=CC=CC1=C43)CC5=CC=C(C=C5)CN6CCOCC6

• Molecular Formula:

  C28H27N3O4

• Molecular Weight:

  469.53

• References & Citations:

  [1]David Proia et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1 (compound 5) |[2]James A. Henderson, et al. Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models. Cancer Res (2021) 81 (13_Supplement) : LB007.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2504233-68-3]